Differential expression of long non‑coding RNAs SRA, HCG22 and MHRT in children with Kawasaki disease

Zhou,Qianqin; Chen,Jiayi; Wu,Danyang; Yan,Haiyian; Liu,Fang; Xi,Yang; Wang,Fuyan; Wu,Junhua; Qiu,Haiyan; Bu,Shizhong

doi:10.3892/etm.2021.10454

Differential expression of long non‑coding RNAs SRA, HCG22 and MHRT in children with Kawasaki disease

Authors:
- Qianqin Zhou
- Jiayi Chen
- Danyang Wu
- Haiyian Yan
- Fang Liu
- Yang Xi
- Fuyan Wang
- Junhua Wu
- Haiyan Qiu
- Shizhong Bu
View Affiliations

Affiliations: Diabetes Research Center, School of Medicine, Ningbo University, Ningbo, Zhejiang 315211, P.R. China, Department of Pediatric Cardiology, Ningbo Women and Children's Hospital, Ningbo, Zhejiang 315012, P.R. China
Published online on: July 15, 2021 https://doi.org/10.3892/etm.2021.10454
Article Number: 1022

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Kawasaki disease (KD) is an acute, self‑limited inflammatory illness during childhood that may lead to thrombosis in the coronary arteries (CA). The major aims of the present study were to estimate the serum levels of long non‑coding RNAs (lncRNAs) and the metabolic profiles of patients with KD. A total of 40 specimens were obtained from pediatric patients (40 specimens before and 40 specimens after treatment) who were diagnosed with KD (n=40). The controls comprised healthy children without KD (n=40). The serum levels of lncRNAs steroid receptor RNA activator (SRA), human leukocyte antigen complex group 22 (HCG22) and myosin heavy chain‑associated RNA transcript (MHRT) were determined using reverse transcription‑quantitative PCR. Subsequently, the correlation between the expression levels of lncRNAs and biochemical parameters of patients was assessed. Receiver operating characteristic curves were constructed to determine the diagnostic value of the lncRNAs. The results indicated that the serum levels of lncRNAs SRA and HCG22 were higher in patients with acute KD compared with those in healthy controls. B‑type natriuretic peptide (BNP) and C‑reactive protein were positively correlated with HCG22 in patients with acute KD, while total cholesterol and low‑density lipoprotein were negatively correlated with HCG22 in patients with acute KD. The lncRNA MHRT was significantly upregulated in convalescent KD compared with acute KD following intravenous immunoglobulin therapy. In patients with convalescent KD, creatine kinase was positively correlated with MHRT, while BNP and adenosine deaminase were negatively correlated with MHRT. In conclusion, to the best of our knowledge, the present study was the first to identify that the serum levels of lncRNAs SRA and HCG22 in patients with acute KD were higher compared with those in control subjects. MHRT levels in patients with convalescent KD were higher than those in the acute phase. LncRNAs SRA and HCG22 may have crucial roles in KD and are potential novel diagnostic biomarkers for KD. LncRNA MHRT may be considered a novel biomarker for predicting the clinical prognosis of patients with KD.

View Figures

View References

1	Kawasaki T: Acute febrile mucocutaneous syndrome with lymphoid involvement with specific desquamation of the fingers and toes in children. Arerugi. 16:178–222. 1967.PubMed/NCBI(In Japanese).
2	Galeotti C, Kaveri SV, Cimaz R, Koné-Paut I and Bayry J: Predisposing factors, pathogenesis and therapeutic intervention of Kawasaki disease. Drug Discov Today. 21:1850–1857. 2016.PubMed/NCBI View Article : Google Scholar
3	Mccrindle BW, Rowley AH, Newburger JW, Burns JC, Bolger AF, Gewitz M, Baker AL, Jackson MA, Takahashi M, Shah P, et al: Diagnosis, treatment, and long-term management of kawasaki disease: A scientific statement for health professionals from the American Heart Association. Circulation. 135:e927–e999. 2017.PubMed/NCBI View Article : Google Scholar
4	Bayers S, Shulman ST and Paller AS: Kawasaki disease: Part I. Diagnosis, clinical features, and pathogenesis. J Am Acad Dermatol. 69:501.e1–e11. 2013.PubMed/NCBI View Article : Google Scholar
5	Takahashi K, Oharaseki T and Yokouchi Y: Pathogenesis of Kawasaki disease. Clin Exp Immunol. 164 (Suppl 1):S20–S22. 2011.PubMed/NCBI View Article : Google Scholar
6	Takahashi K, Oharaseki T and Yokouchi Y: Update on etio and immunopathogenesis of Kawasaki disease. Curr Opin Rheumatol. 26:31–36. 2014.PubMed/NCBI View Article : Google Scholar
7	Orenstein JM, Shulman ST, Fox LM, Baker SC, Takahashi M, Bhatti TR, Russo PA, Mierau GW, de Chadarévian JP, Perlman EJ, et al: Three linked vasculopathic processes characterize Kawasaki disease: A light and transmission electron microscopic study. PLoS One. 7(e38998)2012.PubMed/NCBI View Article : Google Scholar
8	Wapinski O and Chang HY: Long noncoding RNAs and human disease. Trends Cell Biol. 21:354–361. 2011.PubMed/NCBI View Article : Google Scholar
9	Schmitz SU, Grote P and Herrmann BG: Mechanisms of long noncoding RNA function in development and disease. Cell Mol Life Sci. 73:2491–2509. 2016.PubMed/NCBI View Article : Google Scholar
10	Sallam T, Sandhu J and Tontonoz P: Long noncoding RNA discovery in cardiovascular disease: Decoding form to function. Circ Res. 122(155)2018.PubMed/NCBI View Article : Google Scholar
11	Muta H, Ishii M, Yashiro M, Uehara R and Nakamura Y: Late intravenous immunoglobulin treatment in patients with Kawasaki disease. Pediatrics. 129:e291–e297. 2012.PubMed/NCBI View Article : Google Scholar
12	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.PubMed/NCBI View Article : Google Scholar
13	Yang KC, Yamada KA, Patel AY, Topkara VK, George I, Cheema FH, Ewald GA, Mann DL and Nerbonne JM: Deep RNA sequencing reveals dynamic regulation of myocardial noncoding RNAs in failing human heart and remodeling with mechanical circulatory support. Circulation. 129:1009–1021. 2014.PubMed/NCBI View Article : Google Scholar
14	Cooper C, Vincett D, Yan Y, Hamedani MK, Myal Y and Leygue E: Steroid receptor RNA activator bi-faceted genetic system: Heads or Tails? Biochimie. 93:1973–1980. 2011.PubMed/NCBI View Article : Google Scholar
15	Yatagai Y, Hirota T, Sakamoto T, Yamada H, Masuko H, Kaneko Y, Iijima H, Naito T, Noguchi E, Tamari M, et al: Variants near the HLA complex group 22 gene (HCG22) confer increased susceptibility to late-onset asthma in Japanese populations. J Allergy Clin Immunol. 138:281–283.e13. 2016.PubMed/NCBI View Article : Google Scholar
16	Taniguchi N, Konno S, Hattori T, Isada A, Shimizu K, Shimizu K, Shijubo N, Huang SK, Hizawa N and Nishimura M: The CC16 A38G polymorphism is associated with asymptomatic airway hyper-responsiveness and development of late-onset asthma. Ann Allergy Asthma Immunol. 111:376–381.e1. 2013.PubMed/NCBI View Article : Google Scholar
17	Meder B, Rühle F, Weis T, Homuth G, Keller A, Franke J, Peil B, Lorenzo Bermejo J, Frese K, Huge A, et al: A genome-wide association study identifies 6p21 as novel risk locus for dilated cardiomyopathy. Eur Heart J. 35:1069–1077. 2014.PubMed/NCBI View Article : Google Scholar
18	Lu F, Houck JR, Lohavanichbutr P and Chen C: Transcriptome analysis reveals differentially expressed lncRNAs between oral squamous cell carcinoma and healthy oral mucosa. Oncotarget. 8:31521–31531. 2017.PubMed/NCBI View Article : Google Scholar
19	Amano S, Hazama F, Kubagawa H, Tasaka K, Haebara H and Hamashima Y: General pathology of Kawasaki disease: On the morphological alterations corresponding to the clinical manifestations. Acta Pathol Jpn. 30:681–694. 1980.PubMed/NCBI
20	Cabana VG, Gidding SS, Getz GS, Chapman J and Shulman ST: Serum amyloid A and high density lipoprotein participate in the acute phase response of Kawasaki disease. Pediatr Res. 42:651–655. 1997.PubMed/NCBI View Article : Google Scholar
21	Chiang AN, Hwang B, Shaw GC, Lee BC, Lu JH, Meng CC and Chou P: Changes in plasma levels of lipids and lipoprotein composition in patients with Kawasaki disease. Clin Chim Acta. 260:15–26. 1997.PubMed/NCBI View Article : Google Scholar
22	Galeotti C, Bayry J, Kone-Paut I and Kaveri SV: Kawasaki disease: Aetiopathogenesis and therapeutic utility of intravenous immunoglobulin. Autoimmun Rev. 9:441–448. 2010.PubMed/NCBI View Article : Google Scholar
23	Nonoyama S: Immunological abnormalities and endothelial cell injury in Kawasaki disease. Acta Paediatr Jpn. 33:752–755. 1991.PubMed/NCBI View Article : Google Scholar
24	Mostafavi N, Haghjooy-Javanmard S, Presidend N, Manssori NS and Kelishadi R: Persistence of endothelial cell damage late after Kawasaki disease in patients without coronary artery complications. Adv Biomed Res. 4(25)2015.PubMed/NCBI View Article : Google Scholar
25	Leung DY: Clinical and immunologic aspects of Kawasaki disease. Immunodefic Rev. 1:261–271. 1989.PubMed/NCBI
26	Han P, Li W, Lin CH, Yang J, Shang C, Nuernberg ST, Jin KK, Xu W, Lin CY, Lin CJ, et al: A long noncoding RNA protects the heart from pathological hypertrophy. Nature. 514:102–106. 2014.PubMed/NCBI View Article : Google Scholar
27	De Lemos JA, Mcguire DK and Drazner MH: B-type natriuretic peptide in cardiovascular disease. Lancet. 362:316–322. 2003.PubMed/NCBI View Article : Google Scholar